7 recruiting, 2 active not recruiting, 1 completed, 1 unknown. 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 7, Active not recruiting 2, Completed 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow HPV-Related Carcinoma: new trials by email Literature Review of HPV-Related Carcinoma trials Research Report on HPV-Related Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab - Anal Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Jennifer Dorth | 33 | 2026-06-19 | 2026-08-14 |
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer PRGN-2009 plus Pembrolizumab - Cervical Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Precigen, Inc | 24 | 2025-11-11 | 2026-04-23 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes ctDNA test, Pembrolizumab - HPV-Related Carcinoma, Uterine Cervical Cancer | Phase 2 | Recruiting | Instituto do Cancer do Estado de São Paulo | 150 | 2025-03-14 | 2025-12-24 |
| To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, Placebo - HPV Infection, HPV-Related Carcinoma | Phase 2 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 330 | 2025-01-15 | 2025-12-17 |
| Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer Radiation, Platinum based chemotherapy - Oropharynx Cancer, HPV-Related Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 19 | 2023-12-20 | 2026-05-18 |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers E7 TCR-T cells, Aldesleukin - Cervical Cancer, Throat Cancer | Phase 2 | Recruiting | Christian Hinrichs | 20 | 2023-03-07 | 2026-10-28 |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30 - HPV, Oropharynx Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2022-03-24 | 2026-04-13 |
| IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma IPI-549 - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Completed | Assuntina G. Sacco, MD | 16 | 2020-03-06 | 2025-07-25 |
| Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients MEDI0457, Durvalumab - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-09-17 | 2022-07-29 | |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers TG4001, Avelumab - HPV-Related Carcinoma, HPV-Related Cervical Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Transgene | 143 | 2017-09-01 | 2026-02-05 |
Oropharyngeal Neoplasms (5) · Uterine Cervical Neoplasms (4) · Anus Neoplasms (3) · Neoplasm Metastasis (2) · Neoplasms (2) · Penile Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Anal Canal Carcinoma (1) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1)
Neoplasms by Site (10) · Neoplasms (9) · Head and Neck Neoplasms (6) · Urogenital Diseases (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Otorhinolaryngologic Diseases (5) · Otorhinolaryngologic Neoplasms (5) · Pharyngeal Diseases (5) · Pharyngeal Neoplasms (5) · Stomatognathic Diseases (5) · Urogenital Neoplasms (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4)
Adoptive Transfer (2) · aldesleukin (2) · pembrolizumab (2) · Carboplatin (1) · Chemoradiotherapy (1) · Cisplatin (1) · Clinical Trials, Phase II as Topic (1) · Costs and Cost Analysis (1) · Drug Therapy (1) · IPI-549 (1) · MEDI0457 (1) · Platinum Compounds (1) · Radiation (1) · Radiotherapy, Intensity-Modulated (1) · TG4001 vaccine (1)
Christian Hinrichs (2) · Assuntina G. Sacco, MD (1) · Institut Bergonié (1) · Instituto do Cancer do Estado de São Paulo (1) · Jennifer Dorth (1) · Memorial Sloan Kettering Cancer Center (1) · Precigen, Inc (1) · Shanghai Bovax Biotechnology Co., Ltd. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Transgene (1) · University of Michigan Rogel Cancer Center (1)
United States (9) · France (2) · Brazil (1) · China (1) · Spain (1)
Christian S Hinrichs, MD (2) · Acharf Shamseddine, MD (1) · Carole Fakhry, MD, MPH (1) · Ezra Cohen, MD (1) · Jennifer Dorth, MD, MHSc (1) · Maria DP Estevez Diz, Doctor (1) · Michelle Mierzwa (1) · Yi Mo, Master (1)
PMID 34965951, PMID 34998048, PMID 37506588, PMID 40204996, PMID 40579407
2016 (1), U01CA287904 (1)